



## ***NEWS RELEASE***

Media Contact:

Judy Masucci

(412)770-2353

E-Mail: [pr@cellomics.com](mailto:pr@cellomics.com)

### **Fisher Biosciences strengthens its reagent portfolio through acquisition of BioImage**

PITTSBURGH, April 26, 2006 –Fisher Biosciences has acquired BioImage to expand its offering in high content screening and analysis reagent technologies.

BioImage, which is based in Copenhagen, Denmark, complements Fisher Biosciences' existing Cellomics business. The Cellomics platform includes automated imaging instrumentation, BioApplication image analysis software, High Content Informatics software and HitKit® HCS Reagent kits. The entire Cellomics product portfolio is fully integrated to improve the quality and productivity of high content cell-based assays. BioImage is a leader in the field of High Content Pathway analysis, providing the life-science market with products, services and licenses that are based on its Redistribution® technology. Redistribution is a patented technology that monitors protein translocation within a cell and is the basis for many of today's high content assays.

- more -

## *Fisher strengthens its reagent portfolio through acquisition of BioImage - 2*

“The addition of BioImage further enhances our portfolio of high content cell-based assays and reagents,” said Ron Lowy, president and chief executive officer of Fisher Biosciences. “Adding BioImage’s Redistribution IP, assays, cell-lines and services to our already strong offering of high content screening instrumentation, software, siRNA and assay reagent kits, provides a more complete range of options to customers and strengthens Fisher’s leadership position in high content screening.”

Fisher will continue operations in Copenhagen.

### **About Fisher Biosciences**

Fisher Biosciences, a unit of Fisher Scientific International Inc., manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas. From fine and high-purity chemicals, clinical diagnostics, proprietary protein-research and cell-culture products, and sterile-liquid-handling systems, to innovative RNA-interference technology and high content screening, Fisher Biosciences serves scientific-research, healthcare, drug-discovery, and general industrial customers around the world. For more information please visit [www.fisherbiosci.com](http://www.fisherbiosci.com).

### **About Cellomics**

Cellomics, a business unit within the Fisher Biosciences group, provides complete systems for High Content Screening (HCS) and Analysis (HCA) to drug discovery and systems biology researchers. The Cellomics platform includes automated imaging instrumentation (ArrayScan® and KineticScan® HCS Readers and the cellWoRx™ High Content Cell Analysis System), BioApplication image analysis software, High Content Informatics (HCi™), and HitKit® HCS Reagent Kits, fully integrated to improve the quality and productivity of cell-based assays. Cellomics' proprietary platforms are in use at multiple sites within the top 15 pharmaceutical companies, as well as leading biotechnology companies and academic centers throughout the world. For more information about Cellomics-brand products and services, please visit [www.cellomics.com](http://www.cellomics.com) or call 412-770-2200.

*Fisher Strengthens its reagent portfolio through acquisition of BioImage - 3*

**About BioImage**

BioImage A/S is a life science company based in the Medicon Valley area around Copenhagen, Denmark. The company has pioneered the field of High Content Pathway Analysis, providing products, services, and broadly enabling licenses to the life science market that are based on the Redistribution technology. Redistribution is a patented technology that monitors protein translocation within a cell and is the basis for many of today's high content assays. BioImage was spun out of Novo Nordisk A/S in 1999 with venture funds advised by Apax Partners. For more information, please refer to [www.bioimage.com](http://www.bioimage.com)